GSK Plc has made a significant agreement with Chimagen Biosciences, a Chinese biotech firm, to acquire an experimental drug for expanding its lupus treatment pipeline.
The deal involves an upfront payment of $300 million, with the potential for Chimagen to receive an additional $550 million based on the drug's success.
The antibody drug, currently in early clinical trials for leukemia and lymphoma, is expected to begin early trials for lupus in 2025.
This acquisition highlights GSK's dedication to developing innovative therapies for autoimmune diseases.